Microwave thermoradiotherapy was used as a primary treatment for 44 patients with choroidal melanoma. An episcleral dishshaped microwave antenna was placed beneath the tumour at the time of plaque brachytherapy. While temperatures were measured at the sclera, the tumour's apex was targeted to receive a minimum of 42°C for 45 minutes. In addition, the patients received full or reduced doses of plaque radiotherapy. No patients have been lost to foliow-up. Two eyes have been enucleated: one for rubeotic glaucoma, and one for uveitic glaucoma. Though six patients have died, only one death was due to metastatic choroidal melanoma (39 months after treatment). Clinical observations suggest that the addition of microwave heating to plaque radiation therapy of choroidal melanoma has been weli tolerated. There has been a 97-7% local control rate (with a mean follow-up of 22.2 months). We have reduced the minimum tumour radiation dose (apex dose) to levels used for thermoradiotherapy of cutaneous melanomas (50 Gy/5000 rad). Within the range of this foliow-up period no adverse effects which might preclude the use of this microwave heat delivery system for treatment of choroidal melanoma have been noted.
Heat has been shown to potentiate radiation in the treatment of cancer."' This is because hyperthermia can directly kill cells, it can inactivate cellular enzymes (for example, those used to repair radiation damage), and high level heating can damage blood vessels.7-'3 While all tissues are primarily cooled by blood flow, neoplastic tissues are particularly heat sensitive. This is thought to be because they have poorly developed vascular systems which are often redundant and inefficient, leading to poor perfusion, necrosis, acidosis, and hypoxia. I'l8 When heat is delivered to a cancer, the poorly perfused (radiation resistant) areas concentrate heat and are preferentially damaged.17 18 For effective clinical hyperthermia it is necessary that heat delivery systems be tailored to account for the blood flow and location of the tumour. Ideal heat distributions target the neoplasm and/or its vascular supply with relative sparing of normal tissues. Choroidal melanomas seem uniquely vulnerable to microwave thermotherapy. These are comparatively small tumours which project into the avascular vitreous and are therefore largely dependent on basal blood vessels emanating from the choroid. Episcleral application of a microwave plaque targets the base of an intraocular tumour and preferentially heats its vascular supply.`9-2 The only normal structures to receive high dose thermotherapy are the relatively heat resistant sclera and cornea directly beneath the episcleral plaque.22 23 In this series microwave thermotherapy was used in conjunction with plaque radiotherapy for treatment of 44 patients with choroidal melanoma. Encouraged by early reductions of tumour height, we reduced the minimum tumour radiation dose (tumour apex) to levels used in treatment of cutaneous melanomas. [1] [2] [3] The associated reductions in radiation to normal ocular structures should decrease the incidence of radiation-associated complications.
This report includes a description of microwave plaque construction, the technique of treatment, microwave and radiation dosimetry, and clinical observations.
Materials and methods
All patients in this series were diagnosed as having choroidal melanoma by clinical examination. Since the time we joined the Collaborative Ocular Melanoma Study (COMS) all eligible patients were told of two standard methods of treatment available to them through participation in the COMS. 24 Ineligible patients and those who refused to join the study were offered observation, enucleation, radiation, or radiation with microwave hyperthermia. This involved a detailed discussion of the risks and benefits of each therapeutic form as it related to their tumour's size, location, and risk of metastasis.
Hospital Internal Review Board (IRB) approvals and a United States of America, Food and Drug Administration investigational device exemption (IDE) were obtained prior to this clinical study. All patients were informed of the investigative nature of microwave thermotherapy. They were told of how many patients had been treated, how long they had been followed-up for complications or recurrence, and the significance of those facts. The mechanism of action of adjuvant heat therapy in other tumour systems, and the rationale for reducing the amount of ionising radiation delivered to the tumour's apex were also explained as well as possible. 1-3 Though no significant scleral damage has been noted in this series, the possibility of such damage (as noted in preclinical studies) was discussed. 20 The patients had a complete eye examination prior to treatment. After refraction, pupillary, ocular motor, and slit-lamp examinations were performed. Goldmann To monitor temperatures during treatment three copper-constantan thermocouples were affixed (cyanoacrylate to the anterior surface of the microwave antenna and bent 900 to bring the thermocouple tips into contact with the sclera. The anterior surface of the microwave dish was insulated up to the tips of the thermocouples 68  47  45  12  2  200  54  85  113  47  45  52  3  211  62  88  125  48  45  48  4  454  141  40  40  50  45  55  5  219  66  80  110  50  45  48  6  535  156  66  40  52-5  45  29  7  124  37  58  110  52  45  21  8  302  70  79  85  50  45  36  9  236  45  63  118  52  45   44  10  263  89  59  58  49  45  46  1 1  193  59  68  98  49-3  45  42  12  132  41  52  120  47-1  45  1 1  13  221  67  60  89  46-9  45  34  14  143  44  59  80  47-3  45  36  15  204  43  64  95  50-1  45  31  16  111  39  50  90  48-7  45  32  17  162  34  50  140  49-4  45  26  18  130  45  53  57  49-7  45  11  19  228  66  50  68  49 5  45  19  20  164  57   49  60  48  45  2 1  21  262  81  52  80  49-5  45  24  22  175  41  56  48  50-5  45  12  23  378  95  5 1  37  50  45  24  24  228  57  55  78  49-7  45  24  25  148  30  48  93  47-3  45  18  26  215  56  52  73  49-5  45  18  27  176  27  45  58  48  45  18  28  200  50  48  100  48-4  45  18  29  153  39  60  88  47-6  45  8  30  257  60  50  69  46-6  45  12  31  201  47  45  62  47-4  45  15  32  292  73  55  76  47-3  45  18  33  165  42  56  116  47  45  16  34  296  74  53  74  49-5  45  12  35  206  52  55  70  48  45  10  36  290  91  50  67  47 4  45  12  37  151  34  50  70 47 (Table 2) .
The second group, the largest and the most notable set of 29 be attributed to microwave thermotherapy. The first and most important has been chorioretinal attenuation within and anterior to the treatment zone (Fig 2) . No evidence of scleral damage has been noted on either ophthalmoscopy or ultrasonography. This reaction has been noted in a total of 13 patients (12 ofwhom were treated with 'field-off technique). The second side effect may be related to this chorioretinal reaction. Eyes with tumours anterior to the equator or involving the ciliary body were noted to have persistently decreased intraocular pressure (without hypotony). The third side effect was a relatively non-progressive anterior subcapsular cataract noted in patient 17 immediately after surgery (Table 3A) . In 44 patients there has been one possible failure of local control (defined as documented tumour growth greater than 15% in apical height). Patient 32's tumour was 10x 0x6 6 4; after 18 months his tumour has grown to 7-4 mm, while its basal dimension has remained unchanged. This tumour was treated to a basal radiation dose of 292 Gy, an apical radiation dose of 55 Gy, and is being followed-up for further documentation of growth.
There have been two enucleations, one in patient 10 for glaucomatous complications of a bilateral uveitis 39 months after treatment, the second in patient 19 (Table 3B) . Both occurred in patients with pre- Pre-tx=pretreatment; post-tx=post-treatment.
Finger existing diabetes, and in one (patient 18) blood dissected to the macula and caused persistent decreased vision (Table 4) .
Patterns of visual acuity change were largely dependent on pre-existing ocular conditions: the proximity ofthe tumour to the fovea, the presence of retinal (foveal) detachment, vitreous haemorrhage, cataract, and cystoid macular oedema. Postoperative patterns were largely dependent on the resolution of foveal detachments, vitreous haemorrhages, the development ofcataract (radiation and non-radiation induced), the appearance of radiation maculopathy, and/or cystoid macular oedema. At this follow-up interval 13 patients have lost two or more lines of vision (includirig the two patients whose eyes were enucleated). Among the 11 remaining patients who experienced serious visual loss, the condition in two was primarily caused by persistent retinal detachments through their foveas, in two it was due to treatment-associated cataract formation, in two due to natural progression of pre-existing cataracts, in two due to increased diabetic retinopathy, in one to perioperative subretinal haemorrhages with secondary macular damage, in one to an exacerbation of a pre-existent cystoid macular oedema, and in one to internal limiting membrane wrinkling through his fovea. Five patients are currently experiencing improvement of two or more lines in visual acuity. Four were secondary to resolved foveal detachments, and one has been due to resolution of his cystoid macular oedema (Table 4) . (Table 4) .
Six patients have died: three of heart di one of sepsis, one of metastatic prostate c; and one patient ofmetastatic choroidal mela (39 months after treatment) ( Table 4) .
Discussion
In the treatment of choroidal mela radiotherapy has been used to stop tu growth or achieve shrinkage in over 9( cases.4" 4 After treatment 30 to 40% o have experienced significant radiation-asso ocular complications.49-55 The incidence location of complications were related 1 method of radiation delivery, the size ( tumour (therefore the amount of rad delivered to the eye), the location of the tui and its response to radiotherapy.
In plaque treatment a radioactive devic sutured to the sclera beneath the intra tumour. Radiation then travelled throug was absorbed by the eye wall, the tumou vitreous, and by normal ocular structure decrease radiation-associated complicatior 
